Shaping the Future of
Pharmaceuticals
Pioneering innovation in Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. Backed by over four decades of industry expertise, backward-integrated manufacturing, and premier global regulatory approvals.
Core Value Pillars Driving Excellence
Engineered to provide global pharmaceutical innovators and generic leaders with uncompromised quality, purity, and supply chain security.
Trusted by Global Regulators
Compliance and quality assurance validated by premier international health agencies including USFDA, EDQM, PMDA Japan, and KFDA Korea.
Innovative Portfolio Expansion
Continual expansion into high-value molecules, niche chemical entities, and 4 to 7 new API molecules added annually to our commercial pipeline.
Commitment to Excellence
Backward integrated manufacturing guaranteeing purity, cost leadership, supply reliability, and continuous manufacturing lead times.
Comprehensive Expertise Across the Pharmaceutical Lifecycle
Promoted by a prominent pharmaceutical house with over four decades of industry experience. Leveraging science and technology to make a profound impact.
Research & Development (R&D)
Our R&D facility strives to develop and drive innovative synthetic techniques and technologies, playing a vital role in enhancing global therapeutic access.
Quality Control & Assurance
Comprehensive organisational structure, validated procedures, and GLP/GDP compliance ensuring every batch meets international pharmacopoeial standards.
Regulatory Compliance
Robust and agile regulatory filings across USFDA, EDQM (6 COS approvals), PMDA Japan, and KFDA Korea, with active filings for ANVISA and cFDA.
CDMO & Custom Synthesis
Integrated from concept to commercialisation with backward integration, green biocatalysis, and continuous manufacturing lead times of 8–10 weeks.
Approved Sites & Regulatory Accreditations
Validated by global health authorities to ensure seamless regulatory filings and audit-readiness for clients.
USFDA
(United States)USFDA Approved
Approved Manufacturing Site for Active Pharmaceutical Ingredients
EDQM
(Europe)6 COS Approvals
Approved Sites & 6 Certificates of Suitability (COS)
PMDA
(Japan)PMDA Accredited
Accredited Foreign Manufacturer for Pharmaceutical Ingredients
KFDA
(South Korea)KFDA Approved
Korean FDA Approved Manufacturing & Quality Systems
ANVISA
(Brazil)ANVISA Active Filing
Approvals actively under pursuit for key commercial molecules
cFDA
(China)cFDA Active Filing
Filing and approvals actively progressing for global supply
Key Active Pharmaceutical Ingredients
Manufactured continuously with maximum lead times of 8 to 10 weeks for dependable supply chain continuity.
AIPAU (Allyl Isopropyl Acetyl Urea)
Therapeutic: Sedative / Hypnotic Intermediate
Benfotiamine
Therapeutic: Synthetic Vitamin B1 / Neuropathy
Dapagliflozin Propanediol
Therapeutic: Antidiabetic / SGLT2 Inhibitor
Lacosamide
Therapeutic: Antiepileptic / CNS
Levetiracetam
Therapeutic: Anticonvulsant / CNS
Linagliptin
Therapeutic: Antidiabetic / DPP-4 Inhibitor
Manufacturing Excellence that Protects the Planet & Empowers People
From our 2,000 L/hr drinking water RO plant in Chandrapadiya village to 12,000+ Miyawaki trees planted and our commitment to Net Zero GHG by 2050, sustainability is woven into every synthesis at Chieron.